Clinical Trials Directory

Trials / Completed

CompletedNCT00003146

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

A Phase II Trial of Thiotepa, Busulfan, and Melphalan Followed by Autologous or Syngeneic Marrow or Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
Sponsor
Fred Hutchinson Cancer Center · Academic / Other
Sex
All
Age
70 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow or peripheral stem cell transplantation in treating patients with multiple myeloma.

Detailed description

OBJECTIVES: I. Assess the toxicity and efficacy at the maximum tolerated dose of busulfan, melphalan, and thiotepa in patients with multiple myeloma. OUTLINE: This is a single arm, open label study. Peripheral blood stem cells (PBSC) are collected and cryopreserved, or bone marrow is harvested and stored, until infusion on day 0. Patients receive oral busulfan every 6 hours on days -8, -7, and -6. Melphalan is administered by continuous IV infusion over 30 minutes on days -5 and -4. Thiotepa is administered by continuous IV infusion over 2 hours on days -3 and -2. Patients undergo PBSC or bone marrow infusion 36-48 hours following the completion of chemotherapy (day 0). Patients are followed for 100 days posttransplant and every 3 months thereafter. PROJECTED ACCRUAL: 30 patients will be accrued.

Conditions

Interventions

TypeNameDescription
DRUGbusulfan
DRUGmelphalan
DRUGthiotepa
PROCEDUREbone marrow transplantation
PROCEDUREperipheral blood stem cell transplantation

Timeline

Start date
1997-11-01
Primary completion
2001-06-01
Completion
2001-06-01
First posted
2004-04-23
Last updated
2011-06-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00003146. Inclusion in this directory is not an endorsement.